Last update Aug. 5, 2022

Dioxipregnen; Pregnenedione

Compatible

Safe substance and/or breastfeeding is the best option.

It is a natural hormone secreted by the ovaries, adrenal glands and placenta. The synthetic form is used in contraception, control of abnormal uterine bleeding, maintenance of pregnancy, and prevention of endometrial hyperplasia. Oral, vaginal, intramuscular administration or as a component of an intrauterine device .

Excreted into breast milk in a non-significant amount. (Croxatto 1987)

No problems have been observed in infants whose mothers have taken it. (Wamboldt 2021, Roy 2020, Reisman 2018, Massai 1999, Chen 1998, Díaz 1997, Shaaban 1991, Díaz​​ 1985 y 1984, Croxatto 1982)

The plasma levels in those infants have been undetectable or very low. (Croxatto 1987)

Progesterone does not affect the production of breast milk or the establishment and duration of breastfeeding. (Carr 2016, Allen 2016, Phillips 2016, Berens 2015, Massai 2005 y 1999, Sivin 1997)

During lactation progestin-only contraceptives are preferable to combined contraceptives. During the first 4 to 6 weeks after birth, non-hormonal methods are of choice as contraceptives. If associated to estrogens may inhibit lactation. It is recommended the use of contraceptive medication that does not contain estrogens, or, better if it contains progestogen alone. (Berens 2015, CDC 2013, Rowe 2013, Amir 2011, Erkkola 2005, WHO 1994)

American Academy of Pediatrics: medication usually compatible with breastfeeding. (AAP 2001)

Alternatives

We do not have alternatives for Dioxipregnen; Pregnenedione since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Dioxipregnen; Pregnenedione is also known as Progesterone. Here it is a list of alternative known names::


Dioxipregnen; Pregnenedione in other languages or writings:

Groups

Dioxipregnen; Pregnenedione belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Dioxipregnen; Pregnenedione in its composition:

List of 29 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Baja - Low %
Molecular weight 315 daltons
Protein Binding 96 - 99 %
Tmax Oral: 2 - 6 / vaginal: 25 -50 hours
T½ 0.1 - 0.3 hours
Theoretical Dose 0.0009 mg/Kg/d

References

  1. Wamboldt R, Shuster S, Sidhu BS. Lactation Induction in a Transgender Woman Wanting to Breastfeed: Case Report. J Clin Endocrinol Metab. 2021 Jan 29. pii: dgaa976. Abstract Full text (link to original source)
  2. Roy M, Hazra A, Merkatz R, Plagianos M, Alami M, Gaur LN, Aruldas K, Sussman H, Variano B, Sitruk-Ware R; Progesterone Vaginal Ring Study Group at Participating Centers.. Progesterone vaginal ring as a new contraceptive option for lactating mothers: Evidence from a multicenter non-randomized comparative clinical trial in India. Contraception. 2020 Sep;102(3):159-167. Abstract Full text (link to original source)
  3. Reisman T, Goldstein Z. Case Report: Induced Lactation in a Transgender Woman. Transgend Health. 2018 Jan 1;3(1):24-26. Abstract Full text (link to original source) Full text (in our servers)
  4. Phillips SJ, Tepper NK, Kapp N, Nanda K, Temmerman M, Curtis KM. Progestogen-only contraceptive use among breastfeeding women: a systematic review. Contraception. 2016;94:226-52. Abstract Full text (link to original source) Full text (in our servers)
  5. Allen SS, Allen AM, Lunos S, Tosun N. Progesterone and Postpartum Smoking Relapse: A Pilot Double-Blind Placebo-Controlled Randomized Trial. Nicotine Tob Res. 2016 Nov;18(11):2145-2153. Epub 2016 Aug 18. Abstract Full text (link to original source)
  6. Carr SL, Gaffield ME, Dragoman MV, Phillips S. Safety of the progesterone-releasing vaginal ring (PVR) among lactating women: A systematic review. Contraception. 2016 Sep;94(3):253-61. Abstract Full text (link to original source)
  7. Berens P, Labbok M; Academy of Breastfeeding Medicine. ABM Clinical Protocol #13: Contraception During Breastfeeding, Revised 2015. Breastfeed Med. 2015 Abstract Full text (link to original source) Full text (in our servers)
  8. CDC. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC). U.S. Selected Practice Recommendations for Contraceptive Use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. MMWR Recomm Rep. 2013 Abstract Full text (link to original source) Full text (in our servers)
  9. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  10. RamaRao S, Clark H, Merkatz R, Sussman H, Sitruk-Ware R. Progesterone vaginal ring: introducing a contraceptive to meet the needs of breastfeeding women. Contraception. 2013 Abstract
  11. Amir LH, Pirotta MV, Raval M. Breastfeeding--evidence based guidelines for the use of medicines. Aust Fam Physician. 2011 Sep;40(9):684-90. Review. Abstract Full text (link to original source) Full text (in our servers)
  12. Erkkola R, Landgren BM. Role of progestins in contraception. Acta Obstet Gynecol Scand. 2005 Abstract Full text (link to original source)
  13. Massai R, Quinteros E, Reyes MV, Caviedes R, Zepeda A, Montero JC, Croxatto HB. Extended use of a progesterone-releasing vaginal ring in nursing women: a phase II clinical trial. Contraception. 2005 Abstract
  14. AAP - American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776-89. Abstract Full text (link to original source) Full text (in our servers)
  15. Massai R, Miranda P, Valdés P, Lavín P, Zepeda A, Casado ME, Silva MA, Fetis G, Bravo C, Chandía O, Peralta O, Croxatto HB, Díaz S. Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception. 1999 Abstract
  16. Chen JH, Wu SC, Shao WQ, Zou MH, Hu J, Cong L, Miao L, Wang C, Dong J, Gao J, Xiao BL. The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women. Contraception. 1998 Abstract
  17. Díaz S, Zepeda A, Maturana X, Reyes MV, Miranda P, Casado ME, Peralta O, Croxatto HB. Fertility regulation in nursing women. IX. Contraceptive performance, duration of lactation, infant growth, and bleeding patterns during use of progesterone vaginal rings, progestin-only pills, Norplant implants, and Copper T 380-A intrauterine devices. Contraception. 1997 Abstract
  18. Sivin I, Díaz S, Croxatto HB, Miranda P, Shaaban M, Sayed EH, Xiao B, Wu SC, Du M, Alvarez F, Brache V, Basnayake S, McCarthy T, Lacarra M, Mishell DR Jr, Koetsawang S, Stern J, Jackanicz T. Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD. Contraception. 1997 Abstract
  19. WHO. Progestogen-only contraceptives during lactation: II. Infant development. World Health Organization, Task Force for Epidemiological Research on Reproductive Health; Special Programme of Research, Development, and Research Training in Human Reproduction. Contraception. 1994 Abstract
  20. Shaaban MM. Contraception with progestogens and progesterone during lactation. J Steroid Biochem Mol Biol. 1991 Abstract
  21. Croxatto HB, Díaz S. The place of progesterone in human contraception. J Steroid Biochem. 1987;27(4-6):991-4. Review. Abstract
  22. Díaz S, Jackanicz TM, Herreros C, Juez G, Peralta O, Miranda P, Casado ME, Schiapacasse V, Salvatierra AM, Brandeis A, et al. Fertility regulation in nursing women: VIII. Progesterone plasma levels and contraceptive efficacy of a progesterone-releasing vaginal ring. Contraception. 1985 Dec;32(6):603-22. Abstract
  23. Díaz S, Peralta O, Juez G, Herreros C, Casado ME, Salvatierra AM, Miranda P, Croxatto HB. Fertility regulation in nursing women. VI. Contraceptive effectiveness of a subdermal progesterone implant. Contraception. 1984 Oct;30(4):311-25. Abstract
  24. Croxatto HB, Díaz S, Peralta O, Juez G, Casado ME, Salvatierra AM, Durán E. Fertility regulation in nursing women. II. Comparative performance of progesterone implants versus placebo and copper T. Am J Obstet Gynecol. 1982 Sep 15;144(2):201-8. Abstract

Total visits

4,113

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM